Paper · 25399552

Nivolumab in previously untreated melanoma without BRAF mutation.

Robert C and 27 others. N Engl J Med, 2015. Cited by 4,564 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Nivolumab in previously untreated melanoma without BRAF mutation. Papers, record 25399552. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25399552

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Nivolumab in previously untreated melanoma without BRAF mutation.; PubMed
Journal: N Engl J Med; PubMed
Year: 2015; PubMed
Publication types: Clinical Trial, Phase III, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/25399552/; PubMed
DOI: https://doi.org/10.1056/nejmoa1412082; PubMed
The journal: https://conductscience.org/library/journal-index/0255562; PubMed
Citations, by iCite: 4,564; iCite
Relative citation ratio, by iCite: 143; iCite
Revised in PubMed: 2023-04-13; PubMed

Authors28

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Robert C	Caroline
2	Long GV	Georgina V
3	Brady B	Benjamin
4	Dutriaux C	Caroline
5	Maio M	Michele
6	Mortier L	Laurent
7	Hassel JC	Jessica C
8	Rutkowski P	Piotr
9	McNeil C	Catriona
10	Kalinka-Warzocha E	Ewa

1 to 10 of 28Source PubMed

See all 28 authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Antibodies, Monoclonal	Major topic
Antineoplastic Agents	Major topic
Dacarbazine	Major topic
Melanoma	Major topic
Programmed Cell Death 1 Receptor	Major topic
Adolescent
Adult
Aged
Aged, 80 and over
Disease-Free Survival
Double-Blind Method
Female
Humans
Male
Middle Aged
Nivolumab
Proto-Oncogene Proteins B-raf
Survival Rate
Young Adult

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials7

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

Trial	Title	The trial lists it as	Named in the paper's record	Source
NCT01721772	Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma	Derived from the trial	Yes	ClinicalTrials.gov
NCT03700905	Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy	Results		ClinicalTrials.gov
NCT03817125	Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention	Background		ClinicalTrials.gov
NCT04186013	Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer	Results		ClinicalTrials.gov
NCT04663126	Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma	Background		ClinicalTrials.gov
NCT06566391	Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma	Background		ClinicalTrials.gov
NCT07174453	Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies	Background		ClinicalTrials.gov

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

Kind	PMID	Title	In Papers	Source
Comment in	25,482,238	Release the hounds! Activating the T-cell response to cancer.	https://conductscience.org/library/papers/25482238	PubMed
Comment in	25,511,188	Skin cancer. Golden age of melanoma therapy.	https://conductscience.org/library/papers/25511188	PubMed

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by2,874

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4,564 citations.

PMID	Title	Journal	Year	In Papers	Source
42,984,749	Clinical characteristics, management, and outcomes of nivolumab-associated pituitary toxicity: a pooled analysis of published case reports and case series.	Front Endocrinol (Lausanne)	2026	https://conductscience.org/library/papers/42984749	PubMed
42,979,397	Immunobiology and Immune-Related Toxicities of Cancer Immunotherapy: Organ-Specific Immune-Related Adverse Events, Cytokine Release Syndrome, and Immune Effector Cell-Associated Neurotoxicity Syndrome.	J Brown Hosp Med	2026	https://conductscience.org/library/papers/42979397	PubMed
42,964,167	An m5C-associated NSUN5-YBX1-CENPF programme marks melanoma cell states and immune features.	Front Immunol	2026	https://conductscience.org/library/papers/42964167	PubMed
42,957,427	SprintX: mitigating data scarcity in antibody design via synthetic structural prior knowledge dataset.	MAbs	2026	https://conductscience.org/library/papers/42957427	PubMed
42,951,965	Tumour assembloids recapitulate tumour-CAF-T cell crosstalk in renal cancer.	Nature	2026	https://conductscience.org/library/papers/42951965	PubMed
42,926,136	Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial.	Nat Med	2026	https://conductscience.org/library/papers/42926136	PubMed
42,898,955	Nano-/Nanobiotechnology-Augmented Pyroptosis in the Treatment of Triple-Negative Breast Cancer: An Updated Review.	Int J Nanomedicine	2026	https://conductscience.org/library/papers/42898955	PubMed
42,883,829	Peptidoglycan Suppresses Melanoma Growth in a Murine Model with Local Immune Activation.	Int J Mol Sci	2026	https://conductscience.org/library/papers/42883829	PubMed
42,840,951	Advances in IL-2-based cancer immunotherapy and the synergistic role of stem-like CD8+ T cells in IL-2 and PD-1 combination therapy.	Front Immunol	2026	https://conductscience.org/library/papers/42840951	PubMed
42,822,444	Distant lymph nodes compensate for resected tumor-draining lymph nodes during cancer immunotherapy.	Immunity	2026	https://conductscience.org/library/papers/42822444	PubMed

1 to 10 of 2,874

See all 2,874 cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
PDCD1	5,133	Swiss-Prot's references	https://conductscience.org/library/genes/5133	NCBI Gene
BRAF	673	PubTator's text mining	https://conductscience.org/library/genes/673	NCBI Gene
CD274	29,126	PubTator's text mining	https://conductscience.org/library/genes/29126	NCBI Gene

Drugs4

The drugs whose trials, in the Pipelines release, list the paper.

Drug	ChEMBL ID	The trials list it as	Trials	In Drugs and targets	Source
IPILIMUMAB	CHEMBL1789844	Results	1	https://conductscience.org/library/drugs/CHEMBL1789844	ChEMBL
NIVOLUMAB	CHEMBL2108738	Results	2	https://conductscience.org/library/drugs/CHEMBL2108738	ChEMBL
ATEZOLIZUMAB	CHEMBL3707227	Results	1	https://conductscience.org/library/drugs/CHEMBL3707227	ChEMBL
DACARBAZINE	CHEMBL476	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL476	ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25399552

GET https://conductscience.org/api/papers/v1/25399552/authors?page=2

API reference For AI assistants